Morepen Laboratories has received approval from China’s National Medical Products Administration (NMPA) for its Loratadine drug, which is used to treat allergies. This approval, granted by the Center for Drug Evaluation (CDE), is a big step for Morepen as it enters one of the largest pharmaceutical markets in the world.
Morepen is already a market leader in the US, holding over 80% of the generics market share for Loratadine. The company has been exporting this drug to the US for more than 25 years, with API exports valued at Rs. 650 crores.
Also See: Want Thicker Hair? A Breakthrough Protein May Hold the Key to Restoring Your Hair! Read it
Loratadine is a widely used second-generation antihistamine that helps relieve allergy symptoms like hay fever and chronic hives. With this approval, Morepen is set to expand its reach into the Chinese market while strengthening its position as a global leader in the pharmaceutical industry.
